Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Psyence Group Inc. (PSYG) is a publicly listed life sciences company focused on the development and commercialization of natural psychedelic and cannabinoid-based products. The company operates primarily in the emerging psychedelic therapeutics and medical cannabis industries, with an emphasis on regulated and legal markets. Its activities span product development, cultivation, research, and early-stage clinical positioning, targeting both therapeutic and wellness-oriented applications.
The company’s primary business lines include the development of psilocybin-derived compounds and the cultivation and distribution of medicinal cannabis. Psyence Group positions itself as an early mover in jurisdictions where psychedelic substances are legal or decriminalized, particularly leveraging regulatory environments that allow lawful cultivation and research. The company was founded in the late 2010s and evolved from a cannabis-focused strategy into a broader psychedelics and biotechnology platform as regulatory frameworks began to shift globally.
Business Operations
Psyence Group conducts operations through distinct business units focused on psychedelics and cannabis. Its psychedelic activities are primarily carried out through Psyence Therapeutics Corp., which is engaged in the research, development, and commercialization of naturally derived psilocybin products. Revenue generation to date has been limited and primarily associated with cannabis cultivation and early-stage product sales, with psychedelic programs largely in the development and pre-commercial phases.
The company operates both domestically and internationally, with cultivation and research activities outside of Canada in jurisdictions where psilocybin is legal. Psyence Group controls cultivation assets, intellectual property related to natural extraction methods, and early research programs. Data regarding material joint ventures or large-scale commercial partnerships is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Psyence Group aims to establish a vertically integrated platform combining cultivation, product development, and future clinical or therapeutic commercialization. Growth initiatives have focused on expanding psychedelic cultivation capacity, advancing research into naturally sourced psilocybin, and maintaining optionality for future clinical trials or licensing arrangements as regulations evolve.
The company has made targeted investments in cultivation infrastructure and subsidiaries supporting its psychedelics strategy, most notably Psyence Therapeutics Corp. No large-scale acquisitions have been conclusively verified through public disclosures. Psyence Group is positioned within emerging sectors tied to mental health therapeutics, alternative medicine, and biotechnology, though many initiatives remain in early or exploratory stages.
Geographic Footprint
Psyence Group is headquartered in Canada, with operational and investment activities extending into the Caribbean, particularly Jamaica, where psilocybin cultivation and research are legal under local law. This geographic positioning provides the company with regulatory advantages relative to peers operating solely in more restrictive jurisdictions.
Beyond North America and the Caribbean, the company’s global footprint remains limited. There is no conclusive public evidence of material operations in Europe, Asia-Pacific, or South America, though management has indicated interest in international expansion as regulatory conditions permit.
Leadership & Governance
Psyence Group was co-founded by industry participants with backgrounds in capital markets and alternative therapeutics. The leadership team emphasizes regulatory compliance, early market entry, and disciplined capital deployment as core elements of its strategic vision. Governance follows standard public-company practices applicable to issuers listed on Canadian public markets.
Key executives include:
- Neil Maresky – Chief Executive Officer
- Evan Levine – President
- Mary Seddon – Chief Financial Officer
- David Shisel – Director
Information regarding board committee structures and long-term executive succession planning is limited, and certain governance details are inconclusive based on available public sources.